{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:28:29Z","timestamp":1795040909994,"version":"4.10.2"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.semarthrit.2025.152640","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T21:26:46Z","timestamp":1738186006000},"page":"152640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice"],"prefix":"10.1016","volume":"71","author":[{"given":"Adri\u00e1n","family":"Mart\u00edn-Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Loricera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Aldasoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Maiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gal\u00edndez-Agirregoikoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Ferraz-Amaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2025.152640_bib0001","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1573397115666190227194014","article-title":"Giant cell arteritis (GCA): pathogenesis, clinical aspects and treatment approaches","volume":"15","author":"Ciofalo","year":"2019","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221113747","article-title":"Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients","volume":"14","author":"Loricera","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0003","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/rheumatology\/keu329","article-title":"Large-vessel giant cell arteritis: a cohort study","volume":"54","author":"Muratore","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0004","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.11353","article-title":"Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years","volume":"48","author":"Nuenninghoff","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/01.bor.0000197996.04709.4e","article-title":"Large-vessel involvement in giant cell arteritis","volume":"18","author":"Bongartz","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0006","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.3390\/jcm11061588","article-title":"Advances in the treatment of giant cell arteritis","volume":"11","author":"Casta\u00f1eda","year":"2022","journal-title":"J Clin Med [Internet]"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0007","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.autrev.2017.05.014","article-title":"Recent advances in our understanding of giant cell arteritis pathogenesis","volume":"16","author":"Samson","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0008","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/annrheumdis-2016-209351","article-title":"Ustekinumab for the treatment of refractory giant cell arteritis","volume":"75","author":"Conway","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0009","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0010","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","article-title":"EULAR recommendations for the management of large vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0011","doi-asserted-by":"crossref","first-page":"155","DOI":"10.55563\/clinexprheumatol\/0nd4kk","article-title":"A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects","volume":"39","author":"Perrineau","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0012","first-page":"S86","article-title":"Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis","volume":"31","author":"Muratore","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0013","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MD.0000000000000033","article-title":"Relapses in patients with giant cell arteritis","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0014","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.intimp.2015.03.020","article-title":"Biologic therapy in ANCA-negative vasculitis","volume":"27","author":"Loricera","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of Tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0016","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0017","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.semarthrit.2014.12.005","article-title":"Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients","volume":"44","author":"Loricera","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0018","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semarthrit.2019.01.003","article-title":"Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice","volume":"49","author":"Calder\u00f3n-Goercke","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0019","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13075-022-02815-9","article-title":"Intravenous tocilizumab for the treatment of giant cell arteritis: a phase ib dose-ranging pharmacokinetic bridging study","volume":"24","author":"Schmitt","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0020","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","article-title":"Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial","volume":"3","author":"Stone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000570","article-title":"Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. potential clinical usefulness in tocilizumab-treated patients","volume":"3","author":"Prieto-Gonz\u00e1lez","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0022","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/annrheumdis-2021-220347","article-title":"Treatment failure in giant cell arteritis","volume":"80","author":"Unizony","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0023","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.23901","article-title":"Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta-analysis","volume":"72","author":"Mainbourg","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0024","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae644","article-title":"Sustained drug-free remission in giant cell arteritis","author":"Narv\u00e1ez","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0025","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/zr7s0g","article-title":"Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry","author":"Alibaz-\u00d6ner","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0026","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00296-023-05527-8","article-title":"Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis","volume":"44","author":"Tsalapaki","year":"2024","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0027","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3899\/jrheum.141347","article-title":"Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study","volume":"42","author":"Kermani","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0028","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.160466","article-title":"Giant cell arteritis: visual loss is our major concern","volume":"43","author":"Gonzalez-Gay","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0029","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13075-020-02171-6","article-title":"Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions","volume":"22","author":"Sugihara","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/kev348","article-title":"Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study","volume":"55","author":"Labarca","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0031","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/art.42325","article-title":"2022 American College of Rheumatology\/EULAR classification Criteria for giant cell arteritis","volume":"74","author":"Ponte","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211020917","article-title":"Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review","volume":"13","author":"Prieto-Pe\u00f1a","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0033","first-page":"864","article-title":"Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0034","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/09273948.2016.1231331","article-title":"Efficacy of Anti-IL6-receptor Tocilizumab in refractory cystoid macular edema of birdshot retinochoroidopathy report of two cases and literature review","volume":"25","author":"Calvo-R\u00edo","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0035","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0036","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4081\/reumatismo.2018.1107","article-title":"Contribution of the new 2012 EULAR\/ACR classification criteria for the diagnosis of polymyalgia rheumatica","volume":"70","author":"Muratore","year":"2018","journal-title":"Reumatismo"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0037","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/rheumatology\/keab353","article-title":"Evaluation of revised classification criteria for giant cell arteritis and its clinical phenotypes","volume":"61","author":"Wiberg","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0038","doi-asserted-by":"crossref","first-page":"keae666","DOI":"10.1093\/rheumatology\/keae666","article-title":"Tocilizumab in cranial and extracranial giant cell arteritis: a national multicenter study of 471 cases","author":"Blanco","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0039","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.2337\/dc23-S002","article-title":"2. Classification and diagnosis of diabetes: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152640_bib0040","first-page":"829","article-title":"Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients","volume":"41","author":"Calder\u00f3n-Goercke","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0041","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu Arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0042","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3899\/jrheum.200952","article-title":"Real-world risk of relapse of giant cell arteritis treated with Tocilizumab: a retrospective analysis of 43 patients","volume":"48","author":"Cl\u00e9ment","year":"2021","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152640_bib0043","first-page":"e25","article-title":"Predictors of relapses or recurrences in patients with giant cell arteritis","volume":"29","author":"Gomes de Pinho","year":"2023","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0044","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3899\/jrheum.181127","article-title":"Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis","volume":"47","author":"Dumont","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0045","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211009029","article-title":"Large-vessel involvement is predictive of multiple relapses in giant cell arteritis","volume":"13","author":"de Mornac","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105494","article-title":"Epidemiology and predictors of relapse in giant cell arteritis: a systematic review and meta-analysis","volume":"90","author":"Moreel","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0047","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/acr.20043","article-title":"Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor \u03b1 and interleukin-6) in the long-term followup of patients with giant cell arteritis","volume":"62","author":"Garc\u00eda-Mart\u00ednez","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0048","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S2665-9913(21)00152-1","article-title":"Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study","volume":"3","author":"Christ","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0049","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejim.2024.06.013","article-title":"Effectiveness of Tocilizumab In aortitis and aneurysms associated with giant cell arteritis","volume":"129","author":"Mart\u00edn-Guti\u00e9rrez","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0050","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jcph.826","article-title":"Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA","volume":"57","author":"Abdallah","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0051","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5414\/CP201819","article-title":"Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects","volume":"51","author":"Zhang","year":"2013","journal-title":"Int. J Clin Pharmacol Therap"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0052","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000809","article-title":"Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries","volume":"4","author":"Lauper","year":"2018","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152640_bib0053","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002830","article-title":"Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study","volume":"9","author":"Mekinian","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0054","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","article-title":"Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis","volume":"58","author":"Adler","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2025.152640_bib0055","first-page":"kead604","article-title":"Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England","author":"Quick","year":"2023","journal-title":"Rheumatology (Oxford)"}],"updated-by":[{"DOI":"10.1016\/j.semarthrit.2025.152655","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000}}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T14:52:11Z","timestamp":1741099931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225000113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":55,"alternative-id":["S0049017225000113"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152640","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152640"}}